1
|
Pui CH: Childhood leukemias. N Engl J Med.
332:1618–1630. 1995. View Article : Google Scholar : PubMed/NCBI
|
2
|
Pui CH and Evans WE: Acute lymphoblastic
leukemia. N Engl J Med. 339:605–615. 1998. View Article : Google Scholar
|
3
|
Pui CH and Jeha S: New therapeutic
strategies for the treatment of acute lymphoblastic leukaemia. Nat
Rev Drug Discov. 6:149–165. 2007. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Rowe JM: Prognostic factors in adult acute
lymphoblastic leukaemia. Br J Haematol. 150:389–405. 2010.
|
5
|
Mudry RE, Fortney JE, York T, Hall BM and
Gibson LF: Stromal cells regulate survival of B-lineage leukemic
cells during chemotherapy. Blood. 96:1926–1932. 2000.
|
6
|
Gibson LF: Survival of B lineage leukemic
cells: Signals from the bone marrow microenvironment. Leuk
Lymphoma. 43:19–27. 2002. View Article : Google Scholar
|
7
|
Konopleva M and Andreeff M: Targeting the
leukemia microenvironment. Curr Drug Targets. 8:685–701. 2007.
View Article : Google Scholar
|
8
|
Boyerinas B, Zafrir M, Yesilkanal AE,
Price TT, Hyjek EM and Sipkins DA: Adhesion to osteopontin in the
bone marrow niche regulates lymphoblastic leukemia cell dormancy.
Blood. 121:4821–4831. 2013. View Article : Google Scholar
|
9
|
Meads MB, Hazlehurst LA and Dalton WS: The
bone marrow microenvironment as a tumor sanctuary and contributor
to drug resistance. Clin Cancer Res. 14:2519–2526. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Liu J, Masurekar A, Johnson S, Chakraborty
S, Griffiths J, Smith D, Alexander S, Dempsey C, Parker C, Harrison
S, et al: Stromal cell-mediated mitochondrial redox adaptation
regulates drug resistance in childhood acute lymphoblastic
leukemia. Oncotarget. 6:43048–43064. 2015.PubMed/NCBI
|
11
|
Dosen-Dahl G, Munthe E, Nygren MK,
Stubberud H, Hystad ME and Rian E: Bone marrow stroma cells
regulate TIEG1 expression in acute lymphoblastic leukemia cells:
Role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape. Int J
Cancer. 123:2759–2766. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Lau LF: CCN1/CYR61: The very model of a
modern matricellular protein. Cell Mol Life Sci. 68:3149–3163.
2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chuang JY, Yu NY, Chiang IP, Lai CH, Lin
CD and Tang CH: Cyr61 increases matrix metalloproteinase-3
expression and cell motility in human oral squamous cell carcinoma
cells. J Cell Biochem. 113:1977–1986. 2012. View Article : Google Scholar
|
14
|
Lin BR, Chang CC, Chen LR, Wu MH, Wang MY,
Kuo IH, Chu CY, Chang KJ, Lee PH, Chen WJ, et al: Cysteine-rich 61
(CCN1) enhances chemotactic migration, transendothelial cell
migration, and intravasation by concomitantly up-regulating
chemokine receptor 1 and 2. Mol Cancer Res. 5:1111–1123. 2007.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Fromigue O, Hamidouche Z, Vaudin P,
Lecanda F, Patino A, Barbry P, Mari B and Marie PJ: CYR61
downregulation reduces osteosarcoma cell invasion, migration, and
metastasis. J Bone Miner Res. 26:1533–1542. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Leask A: A sticky situation: CCN1 promotes
both proliferation and apoptosis of cancer cells. J Cell Commun
Signal. 4:71–72. 2010. View Article : Google Scholar
|
17
|
Lee KB, Byun HJ, Park SH, Park CY, Lee SH
and Rho SB: CYR61 controls p53 and NF-κB expression through
PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells.
Cancer Lett. 315:86–95. 2012. View Article : Google Scholar
|
18
|
Lin MT, Chang CC, Chen ST, Chang HL, Su
JL, Chau YP and Kuo ML: Cyr61 expression confers resistance to
apoptosis in breast cancer MCF-7 cells by a mechanism of
NF-kappaB-dependent XIAP up-regulation. J Biol Chem.
279:24015–24023. 2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lee YJ, Lee DM and Lee SH: Production of
Cyr61 protein is modulated by extracellular acidification and
PI3K/Akt signaling in prostate carcinoma PC-3 cells. Food Chem
Toxicol. 58:169–176. 2013. View Article : Google Scholar
|
20
|
Hesler RA, Huang JJ, Starr MD, Treboschi
VM, Bernanke AG, Nixon AB, McCall SJ, White RR and Blobe GC:
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in
pancreatic ductal adenocarcinoma through downregulation of the
nucleoside transporters hENT1 and hCNT3. Carcinogenesis.
37:1041–1051. 2016. View Article : Google Scholar
|
21
|
Long X, Yu Y, Perlaky L, Man TK and Redell
MS: Stromal CYR61 confers resistance to mitoxantrone via spleen
tyrosine kinase activation in human acute myeloid leukaemia. Br J
Haematol. 170:704–718. 2015. View Article : Google Scholar
|
22
|
Zhu X, Song Y, Wu C, Pan C, Lu P, Wang M,
Zheng P, Huo R, Zhang C, Li W, et al: Cyr61 participates in the
pathogenesis of acute lymphoblastic leukemia by enhancing cellular
survival via the AKT/NF-κB signaling pathway. Sci Rep. 6:340182016.
View Article : Google Scholar
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
24
|
Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He
D, Ouyang G, Lin J, Shen B, Shi Y, et al: A critical role of Cyr61
in interleukin-17-dependent proliferation of fibroblast-like
synoviocytes in rheumatoid arthritis. Arthritis Rheum.
60:3602–3612. 2009. View Article : Google Scholar
|
25
|
Rho SB, Woo JS, Chun T and Park SY:
Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in
ovarian carcinoma cells. Biotechnol Lett. 31:23–28. 2009.
View Article : Google Scholar
|
26
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar
|
27
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar
|
28
|
Mirjolet JF, Barberi-Heyob M, Didelot C,
Peyrat JP, Abecassis J, Millon R and Merlin JL: Bcl-2/Bax protein
ratio predicts 5-fluorouracil sensitivity independently of p53
status. Br J Cancer. 83:1380–1386. 2000. View Article : Google Scholar
|
29
|
Kordes U, Krappmann D, Heissmeyer V,
Ludwig WD and Scheidereit C: Transcription factor NF-kappaB is
constitutively activated in acute lymphoblastic leukemia cells.
Leukemia. 14:399–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
30
|
Xue TY, Xu W, An Q, Wu Y, Xu CP and Zhang
XY: Expression of nuclear transcription factor kappaB in childhood
acute lymphoblastic leukemia and its significance. Zhongguo Shi Yan
Xue Ye Xue Za Zhi. 15:767–771. 2007.In Chinese. PubMed/NCBI
|
31
|
Dos Santos NR, Ghezzo MN, da Silva RC and
Fernandes MT: NF-κB in T-cell acute lymphoblastic leukemia:
Oncogenic functions in leukemic and in microenvironmental cells.
Cancers (Basel). 2:1838–1860. 2010. View Article : Google Scholar
|
32
|
Niu CC, Zhao C, Yang Z, Zhang XL, Pan J,
Zhao C and Si WK: Inhibiting CCN1 blocks AML cell growth by
disrupting the MEK/ERK pathway. Cancer Cell Int. 14:742014.
View Article : Google Scholar
|
33
|
Anand S, Penrhyn-Lowe S and Venkitaraman
AR: AURORA-A amplification overrides the mitotic spindle assembly
checkpoint, inducing resistance to Taxol. Cancer Cell. 3:51–62.
2003. View Article : Google Scholar : PubMed/NCBI
|
34
|
Lowe SW and Lin AW: Apoptosis in cancer.
Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI
|
35
|
Chen G, Wang Y, Li M, Xu T, Wang X, Hong B
and Niu Y: Curcumol induces HSC-T6 cell death through suppression
of Bcl-2: Involvement of PI3K and NF-κB pathways. Eur J Pharm Sci.
65:21–28. 2014. View Article : Google Scholar
|
36
|
González-Ramos R, Defrère S and Devoto L:
Nuclear factor-kappaB: A main regulator of inflammation and cell
survival in endometriosis pathophysiology. Fertil Steril.
98:520–528. 2012. View Article : Google Scholar
|
37
|
Cao JP, Niu HY, Wang HJ, Huang XG and Gao
DS: NF-κB p65/p52 plays a role in GDNF up-regulating Bcl-2 and
Bcl-w expression in 6-OHDA-induced apoptosis of MN9D cell. Int J
Neurosci. 123:705–710. 2013. View Article : Google Scholar
|